Skip to main content
Livermore
Livermore
ZHEN

BridgeBio Oncology Therapeutics, Inc.

BBOT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001869105

No open-market purchases or sales by BridgeBio Oncology Therapeutics, Inc. insiders were filed in the last 90 days; 65 institutions reported holding it in 13F filings for Q2 2026, worth $450.6M in total; no superinvestor holds it.

Holders of 5% or more of BBOT

Holders whose latest Schedule 13D or 13G filing reports 5% or more of BridgeBio Oncology Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of BBOT
HolderLatest formStakeChangeFirst filedLatest filingFiling
Helix Holdings II LLC13D/A31.59%7.39M shares–Feb 20, 20242 filingsMar 4, 2025SEC
Helix Holdings II LLC13D/A22.60%17.9M shares–Aug 13, 20251 filingAug 13, 2025SEC
Chen Bihua13D/A22.32%17.9M shares–Jul 6, 20261 filingJul 6, 2026SEC
BridgeBio Pharma LLC13D17.50%13.9M sharesNewAug 18, 20251 filingAug 18, 2025SEC
BlackRock Portfolio Management LLC13G7.90%1.50M sharesNewApr 15, 20251 filingApr 15, 2025SEC
Flynn James E13G6.17%4.89M sharesNewAug 18, 20251 filingAug 18, 2025SEC
BC Global Opportunities IX LP13G5.50%4.37M sharesNewSep 3, 20251 filingSep 3, 2025SEC
Sculptor Capital LP13G5.12%967.5K sharesNewJul 24, 20251 filingJul 24, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

19 Schedule 13D and 13G filings on BridgeBio Oncology Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on BBOT
Filed (ET)FilerFormStakeChangeEvent dateFiling
Jul 6, 20264:37 PM ETChen Bihuaand 7 others13D/A22.32%17.9M shares–Jul 1, 2026SEC
Nov 14, 20254:09 PM ETCitadel Advisors LLCand 6 others13G/A3.20%2.54M shares–Below 5%Sep 30, 2025SEC
Nov 13, 20259:02 AM ETAdage Capital Management, L.P.and 2 others13G/A1.88%1.49M shares–Below 5%Sep 30, 2025SEC
Sep 3, 20253:05 PM ETBC Global Opportunities IX LPand 3 others13G5.50%4.37M sharesNewSep 4, 2025SEC
Aug 18, 20255:59 PM ETFlynn James Eand 5 others13G6.17%4.89M sharesNewAug 11, 2025SEC
Aug 18, 20255:41 PM ETBridgeBio Pharma LLCand 1 other13D17.50%13.9M sharesNewAug 11, 2025SEC
Aug 13, 20258:29 AM ETHelix Holdings II LLCand 3 others13D/A22.60%17.9M shares–Aug 11, 2025SEC
Jul 30, 20254:15 PM ETIntegrated Core Strategies (US) LLCand 3 others13G/A4.70%897.3K shares–Below 5%Jun 30, 2025SEC
Jul 24, 20259:05 PM ETSculptor Capital LPand 6 others13G5.12%967.5K sharesNewJul 17, 2025SEC
Apr 22, 202511:06 AM ETBlackRock, Inc.13G/A0.00%0 shares–Below 5%Mar 31, 2025SEC
Apr 15, 20255:04 PM ETBlackRock Portfolio Management LLC13G7.90%1.50M sharesNewMar 31, 2025SEC
Mar 4, 20256:43 PM ETHelix Holdings II LLCand 3 others13D/A31.59%7.39M shares–Feb 28, 2025SEC
Nov 14, 2024Price T Rowe Associates Inc13GOld format–New–SEC
Nov 8, 2024BlackRock, Inc.13GOld format–––SEC
Oct 22, 2024BlackRock, Inc.13GOld format–New–SEC
Feb 23, 2024Citadel Advisors LLC13GOld format–New–SEC
Feb 23, 2024Adage Capital Partners GP, L.L.C.13GOld format–New–SEC
Feb 20, 2024Helix Holdings II LLC13DOld format–New–SEC
Feb 15, 2024Integrated Core Strategies (US) LLC13GOld format–New–SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell BridgeBio Oncology Therapeutics, Inc. shares.

No Form 144 notices for BridgeBio Oncology Therapeutics, Inc. are on file.